Telix Pharmaceuticals Ltd — Investor Presentation 2021

Nov 15, 2021

==> picture [271 x 234] intentionally omitted <==

==> picture [176 x 97] intentionally omitted <==

Precision Oncology See it. Treat it.

Investor Presentation

November 2021

Disclaimer

==> picture [100 x 56] intentionally omitted <==

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation may contain forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Telix, and its directors, officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Telix’s product pipeline. Actual results from clinical trials may vary from those shown.

Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been approved by the Australian Therapeutic Goods Administration (TGA), and accepted for filing by the U.S. Food and Drug Administration (FDA). Telix is also progressing marketing authorisation applications for Illuccix in the European Union and Canada. With the exception of Illuccix in Australia and Scintimun®, none of Telix’s products have received a marketing authorisation in any jurisdiction.

Telix Pharmaceuticals Limited (ASX: TLX)

An established global leader in radiopharmaceuticals

==> picture [100 x 56] intentionally omitted <==

==> picture [80 x 81] intentionally omitted <==

==> picture [80 x 80] intentionally omitted <==

Extensive portfolio of diagnostic and therapeutic assets with compelling clinical data

12 150 patient doses in past 12 months[1] , 1st marketing authorisation approval for TLX591-CDx (Illuccix[®] ) received[2]

17 active clinical trials (7 indications)[3]

Leading supply chain and distribution network

80[countries in the Telix distribution network] 11[countries with a manufacturing footprint]

==> picture [441 x 398] intentionally omitted <==

1. Clinical trial doses and magisterial / compassionate use of TLX591-CDx. 12 months from Q4 2020

2. Therapeutic Goods Administration (TGA) Australia – ASX 2/11/21 3. Includes partnered investigator-led studies.

Telix Pharmaceuticals Limited (ASX: TLX)

Our strategy: See It. Treat it. Personalised, precision medicine

Targeted radiation delivery Systemically administered

==> picture [85 x 270] intentionally omitted <==

Unique cancer cell signature (target)

==> picture [180 x 151] intentionally omitted <==

==> picture [42 x 55] intentionally omitted <==

==> picture [42 x 55] intentionally omitted <==

Radioactive isotope Targeting agent (a small molecule or antibody) binds selectively to a cancer cell

1. Courtesy of Ammar Chaudhry MD, City of Hope, Duarte CA, USA.

==> picture [100 x 56] intentionally omitted <==

Imaging

TLX591-CDx[1] (Prostate cancer)

==> picture [74 x 10] intentionally omitted <==

----- Start of picture text -----

PET scanner
----- End of picture text -----

==> picture [97 x 85] intentionally omitted <==

==> picture [93 x 143] intentionally omitted <==

==> picture [69 x 143] intentionally omitted <==

68Ga, 89Zr (diagnostic isotopes) Enables PET images of cancer

==> picture [141 x 169] intentionally omitted <==

TLX591 (Prostate cancer)

==> picture [71 x 18] intentionally omitted <==

----- Start of picture text -----

Therapy
----- End of picture text -----

177Lu, 131I, 225Ac (therapeutic isotopes)

Enables precise radiation delivery to the cancer

Telix Pharmaceuticals Limited (ASX: TLX)

Radiation has never been more important in cancer care Underpinned by the shift from radiation “in a box” to radiation “in a shot”

==> picture [100 x 56] intentionally omitted <==

The evolution from external-beam radiation to systematically-delivered and targeted radiation is transforming the role of radiation in cancer care

From a ‘box’

==> picture [323 x 267] intentionally omitted <==

• Synergy between imaging and therapy

• Broad cancer utility

• Potential to enhance existing drug classes (androgens, taxanes etc)

• A vitally important “primer” for immuno-oncology

• A future cornerstone modality for gene/cell therapy conditioning

To a ‘shot’

==> picture [85 x 270] intentionally omitted <==

Telix is driving the integration of nuclear medicine and medical oncology with more targeted and personalised therapy and patient-friendly dosing regimens

Telix Pharmaceuticals Limited (ASX: TLX)

Telix is pioneering a new cancer modality

==> picture [100 x 56] intentionally omitted <==

Kidney Cancer

Ph Name Asset Dx/Tx	Ph Name Asset Dx/Tx	Ph Name Asset Dx/Tx	Ph Name Asset Dx/Tx
III		TLX250-CDx	Dx
I/II		TLX250-CDx	Dx
II	(IIT)	TLX250	Tx
II	(IIT)	TLX250	Tx

Ph Name Asset Dx/Tx I/II TLX101 Tx Glioblastoma	Ph Name Asset Dx/Tx I/II TLX101 Tx Glioblastoma	Ph Name Asset Dx/Tx I/II TLX101 Tx Glioblastoma	Ph Name Asset Dx/Tx I/II TLX101 Tx Glioblastoma
I/II		TLX101	Tx

Breast Cancer

Ph Name Asset Dx/Tx II OPALESCENCE (IIT) TLX250-CDx Dx I Emory University (IIT) TLX591-CDx Dx	Ph Name Asset Dx/Tx II OPALESCENCE (IIT) TLX250-CDx Dx I Emory University (IIT) TLX591-CDx Dx	Ph Name Asset Dx/Tx II OPALESCENCE (IIT) TLX250-CDx Dx I Emory University (IIT) TLX591-CDx Dx	Ph Name Asset Dx/Tx II OPALESCENCE (IIT) TLX250-CDx Dx I Emory University (IIT) TLX591-CDx Dx
II	OPALESCENCE (IIT)	TLX250-CDx	Dx
I	Emory University (IIT)	TLX591-CDx	Dx

Prostate Cancer

						Prostate Cancer	Prostate Cancer	Prostate Cancer	Prostate Cancer
						Ph Name Asset Dx/Tx
						III	University of Linz (IIT)	TLX591-CDx	Dx
						II	Emory University (IIT)	TLX591-CDx	Dx
						II	(IIT)	TLX591-CDx	Dx
						II	Mem. Sloan Kettering (IIT)	TLX591-CDx	Dx
						N/A*		TLX599-CDx	Dx
Bladder Cancer						III		TLX591	Tx
Ph Name Asset Dx/Tx
						I		TLX592	Tx
I	ZiP-UP (IIT)	TLX250-CDx	Dx

Lung Cancer

Ph Name Asset Dx/Tx
I	Royal Adelaide (IIT)	APOMAB		Dx/Tx
Bone Marrow Conditioning
Ph Name Asset Dx/Tx
I/IIa	(IIT)		TLX66		Tx

Ph Name Asset Dx/Tx
I	Royal Adelaide (IIT)	APOMAB		Dx/Tx
Bone Marrow Conditioning
Ph Name Asset Dx/Tx
I/IIa	(IIT)		TLX66		Tx

Bladder Cancer	Bladder Cancer
Ph	Name	Asset	Dx/Tx
I	ZiP-UP (IIT)	TLX250-CDx	Dx

*Registry study

Telix Pharmaceuticals Limited (ASX: TLX)

Core pipeline: Oncology & rare diseases

==> picture [100 x 56] intentionally omitted <==

==> picture [870 x 367] intentionally omitted <==

Shaded arrows indicate completion expectations in the next 12 months.

*Registry study

1. Prostate-specific membrane antigen.

2. Carbonic anhydrase IX.

3. Bone marrow conditioning and rare disease. 5. Cluster of differentiation 66.

4. Large amino acid transporter 1.

Telix Pharmaceuticals Limited (ASX: TLX)

Strategic Priorities

==> picture [145 x 144] intentionally omitted <==

Use Illuccix as a commercial launchpad

Establish Telix’s leadership in the urologic oncology domain

==> picture [179 x 178] intentionally omitted <==

Create a high-value diagnostic portfolio

Kidney cancer imaging agent addresses major unmet need, builds on Illuccix engagement

==> picture [144 x 144] intentionally omitted <==

Deliver on commercial value of therapeutics

Advance late-stage assets in the core pipeline that benefit from diagnostic market entrance

==> picture [104 x 58] intentionally omitted <==

==> picture [144 x 144] intentionally omitted <==

Expand the pipeline

Novel targets, clinical applications and manufacturing technologies

8

Telix Pharmaceuticals Limited (ASX: TLX)

Near-term objectives Unlocking the value in our pipeline

2021

==> picture [71 x 71] intentionally omitted <==

Launch Illuccix Complete ZIRCON

==> picture [71 x 72] intentionally omitted <==

==> picture [68 x 68] intentionally omitted <==

Commence ProstACT

==> picture [100 x 56] intentionally omitted <==

2022

Illuccix commercial rollout Establish a leading presence in the urologic oncology domain

Regulatory filing for kidney cancer imaging product to follow-on Illuccix

Advance late-stage therapeutic portfolio to address significant unmet medical needs

Telix Pharmaceuticals Limited (ASX: TLX)

==> picture [322 x 274] intentionally omitted <==

==> picture [100 x 56] intentionally omitted <==

Telix Pharmaceuticals Limited (ASX: TLX)

Illuccix[® ] approval and rollout milestones US FDA PDUFA[1] goal date 23 December 2021

==> picture [100 x 56] intentionally omitted <==

==> picture [913 x 376] intentionally omitted <==

1. United States Food and Drug Administration (FDA) Prescription Drug User Fee Act, Goal Date

2. Healthcare Common Procedure Coding System

Telix Pharmaceuticals Limited (ASX: TLX)

Illuccix (TLX591-CDx) PSMA-PET[1] imaging A differentiated offering in the PSMA-PET market

==> picture [100 x 56] intentionally omitted <==

• Access to ~90% of eligible PET sites

• On-demand

pharmacy-based production with a high yield product

• Customer and patient scheduling flexibility

==> picture [282 x 195] intentionally omitted <==

----- Start of picture text -----

Telix / partner sites
Current competitor sites
(4 November 2021)
----- End of picture text -----

Illuccix[®] (Kit for the preparation of[68] Ga-PSMA-11) has received marketing authorisation approval in Australia. In all other jurisdictions, including the United States, it is an investigational product and has not attained a marketing authorisation. Product launch in the United States is subject to FDA approval of a New Drug Application (NDA)

1. Prostate-specific membrane antigen (PSMA) Positron emission tomography (PET)

Telix Pharmaceuticals Limited (ASX: TLX)

PSMA-PET imaging emerging as standard of care in prostate cancer Inclusion in guidelines are driving clinical adoption and reimbursement

==> picture [100 x 56] intentionally omitted <==

• Updated National Comprehensive Cancer Network Guidelines® include Ga-68 PSMA-11 PET/CT to be considered as an alternative to standard imaging of bone and soft tissue[1]

• ✓ Conventional imaging no longer a necessary prerequisite to PSMAPET

• ✓ Expanded indication: detection of unfavourable intermediate, high and very high risk as well as recurrent prostate cancer

• Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) recognises higher accuracy in the initial staging evaluation[2]

==> picture [199 x 80] intentionally omitted <==

==> picture [168 x 95] intentionally omitted <==

• Two of the four main Radiology Benefit Managers (RBMs) - AIM Specialty Health[3] and NIA Magellan[4] – are now recommending PSMA-PET representing a significant portion of commercial payor (health insurance) reimbursement policies

==> picture [137 x 55] intentionally omitted <==

1. NCCN® Prostate Cancer Guidelines Update, Version 1.2022 – 10/09/21

2. SNMMI AUC for PSMA-PET Imaging: https://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=38657

3. AIM Clinical Appropriateness Guidelines, Advanced Imaging. AUC: Oncologic Imaging (Effective 7/11/21).

==> picture [199 x 36] intentionally omitted <==

1. National Imaging Associates Magellan Clinical Guidelines For Medical Necessity Review, Advanced Imaging Guideline (Effective 01/01/22)

Telix Pharmaceuticals Limited (ASX: TLX)

Market opportunity expanded Due to growing incidence rates and guideline inclusions

• US patients with prostate cancer eligible for PSMA-PET imaging

1. Primary staging in newly diagnosed high-risk prostate cancer 2. Biochemical recurrence following prostatectomy or radiation therapy

1. Monitoring of response to systemic therapy

2. Patient selection for PSMA targeted radio-ligand therapy (RLT)

US total addressable market (TAM) value

1. Telix markets = US + EU countries included in MAA submission to Danish Medicines Authority on 30 April 2020.

TAM value including EU

==> picture [105 x 210] intentionally omitted <==

----- Start of picture text -----

US (OLD)
146,000
(1) 55,000
(2) 52,000
(3) 22,000
(4) 17,000
----- End of picture text -----

USD $575M USD $900M

==> picture [100 x 56] intentionally omitted <==

==> picture [106 x 253] intentionally omitted <==

----- Start of picture text -----

US (NEW)
194,510
57,000
74,000
35,000
28,000
----- End of picture text -----

USD $725M

USD $1,08B

1. American Cancer Society. Cancer Facts & Figures 2021. Atlanta, GA: American Cancer Society; 2021.

2. GLOBOCAN 2020 incidence of prostate cancer in Telix EU markets.

3. US TAM value = USD $750M, EU TAM value = USD $325M.

Telix Pharmaceuticals Limited (ASX: TLX)

The NOBLE Registry (TLX599-CDx): Nobody left behind Improving access to PSMA imaging

==> picture [100 x 56] intentionally omitted <==

==> picture [126 x 45] intentionally omitted <==

==> picture [114 x 57] intentionally omitted <==

• Collaboration to investigate utility of[99m] Tc-iPSMA SPECT[1] imaging in prostate cancer

• Global consortium of clinical sites and investigators with experience using[99m] Tc-iPSMA

==> picture [45 x 47] intentionally omitted <==

• Geographic focus on developing markets or remote regions where access to PET imaging is limited[2]

• Isotope ([99] Tc) supply chain well established and inexpensive

• Rapid expansion planned including APAC

• Single photon emission computed tomography

• Worldwide SPECT cameras outnumber PET by 4:1 (MEDraysintell 2020)

==> picture [68 x 92] intentionally omitted <==

==> picture [54 x 48] intentionally omitted <==

==> picture [26 x 9] intentionally omitted <==

----- Start of picture text -----

Chair
----- End of picture text -----

==> picture [544 x 327] intentionally omitted <==

----- Start of picture text -----

Dr. Ryan
Yudistiro
Dr. Akintunde Indonesia
Orunmuyi
Nigeria
Peter Tually
Australia
Dr. Mike Sathekge
South Africa
15
----- End of picture text -----

Telix Pharmaceuticals Limited (ASX: TLX)

==> picture [153 x 44] intentionally omitted <==

==> picture [160 x 56] intentionally omitted <==

==> picture [100 x 56] intentionally omitted <==

Telix Pharmaceuticals Limited (ASX: TLX)

Building a high-value diagnostics portfolio “Breakthrough Therapy” designation, clinical leadership opportunity

==> picture [100 x 56] intentionally omitted <==

• TLX250-CDx is an investigational product being developed for the imaging of clear cell renal cell carcinoma (ccRCC) with PET/CT

• Current options for patients are limited, potential for clinical leadership with a non-invasive imaging modality for ccRCC

• Being studied as an imaging agent assessing ability to determine if “indeterminate renal masses” are malignant through improved, whole of body imaging

• May aid decision making and avoids unnecessary surgical intervention

• Biologics License Application (BLA) consultation process to commence by end-year 2021

• Opportunity to follow prostate cancer imaging, with a second high-value product for the genitourinary (GU) oncology field

==> picture [241 x 250] intentionally omitted <==

An example of PET/CT imaging showing the uptake of 89Zr-girentuximab in a primary renal mass. The insert shows the identification of a metastatic lesion of the . proximal radius, confirmed as ccRCC upon biopsy[1]

1. Hekman et al, European Urology (2018).

Telix Pharmaceuticals Limited (ASX: TLX)

ZIRCON Phase III trial of TLX250-CDx for imaging of ccRCC Study overview

==> picture [100 x 56] intentionally omitted <==

==> picture [161 x 46] intentionally omitted <==

Eligible Patients

• Single indeterminate renal mass ≤7cm diameter on CT or MRI suspicious for ccRCC

• • Scheduled for surgical removal as part of management plan

==> picture [325 x 118] intentionally omitted <==

----- Start of picture text -----

Surgical removal
TLX250-CDx
& histology as
PET/CT scan
standard of truth
----- End of picture text -----

==> picture [154 x 117] intentionally omitted <==

• International, multi-centre, Phase III trial in ~252 patients with an indeterminate renal mass suspicious of ccRCC

• ✓ Primary endpoint: Sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect ccRCC in patients with indeterminate renal masses, using histology as standard of truth

• 34 sites participating

• ✓ 75% recruited, progressing well towards completion

• ✓ United States, Canada, Europe, Turkey, Australia

• ZIRDAC-JP Phase I/II bridging trial of TLX250-CDx in Japan

• ✓ Phase I objectives met, Phase II in planning, potential to include Chinese patients to expand Asian utility

Telix Pharmaceuticals Limited (ASX: TLX)

TLX250-CDx: Delivering an unmet need in kidney cancer imaging

==> picture [100 x 56] intentionally omitted <==

• Total addressable market value in US and Europe estimated at US$3-400M

• Potential for market leadership, given limited patient options

• Addresses a major unmet medical need

==> picture [689 x 388] intentionally omitted <==

----- Start of picture text -----

Yearly estimated
Yearly new cases,
number of deaths,
worldwide, both
worldwide, both
sexes, all ages
sexes, all ages
431,288
179,368
----- End of picture text -----

Telix Pharmaceuticals Limited (ASX: TLX)

CA9[1] is an exciting target

New understanding leads to potential for applications beyond kidney cancer

==> picture [100 x 56] intentionally omitted <==

• A transmembrane protein and a tumor-associated carbonic anhydrase isoenzyme

• Over-expressed in mutated ccRCC and many hypoxic solid tumors, with low expression in most normal tissue

• High expression includes cervix, esophagus, lung, breast, colon, brain, and vulval cancers

• Imaging is being used to “indication scout” for future therapy applications

	Potential Indication	Potential Indication	Status
		Bladder or Urothelial Cancer	Commenced
		Triple Negative Breast Cancer	Commenced
		Lung Cancer	In planning
		Ovarian Cancer	In planning
		Colorectal Cancer	In planning
		Head and Neck Cancer	In planning
		Pancreatic Cancer	In planning

1. Carbonic Anhydrase IX (CAIX / CA9)

Telix Pharmaceuticals Limited (ASX: TLX)

STARLITE 2 Phase II trial of TLX250 for Treatment of ccRCC TLX250 in combination with immunotherapy

==> picture [100 x 56] intentionally omitted <==

• Phase II trial of TLX250 plus nivolumab in with ccRCC who have progressed following prior immunotherapy

• Evaluates TLX250-delivered radiation as an immune system “primer” NCT03849118

• NCT03849118

• ✓ Targets carbonic anhydrase IX (CA9)[1] – a protein highly expressed in patients that are likely to demonstrate a more limited response to cancer immunotherapy

• Primary endpoint

• ✓ To determine the safety and efficacy of combination therapy with 177Lugirentuximab (TLX250) as assessed by the number of tumours responding to the Telix therapy versus the current standard of care alone

• FDA Investigational New Drug Application (IND) accepted for STARLITE 2 study, being undertaken at Memorial Sloan Kettering Cancer Centre

• Additional Phase II study – STARLITE 1 - (first-line combination study) to be initiated at a second US site (submission in progress)

==> picture [281 x 351] intentionally omitted <==

CA9 expression is correlated with the presence of tumour-infiltrating lymphocytes, which may confer resistance to immunotherapy. 21

1. Giatromanolaki et al. British Journal of Cancer . 2020.

Telix Pharmaceuticals Limited (ASX: TLX)

==> picture [100 x 56] intentionally omitted <==

==> picture [240 x 120] intentionally omitted <==

Telix Pharmaceuticals Limited (ASX: TLX)

ProstACT program overview Multiple opportunities to deliver insights into TLX591

==> picture [221 x 69] intentionally omitted <==

Radiogenomics study

• ~50 patients

• First line mCRPC

• Rapid recruitment

Treat the scan

Correlation between imaging and therapy to optimise patient selection

Combination with EBRT in oligometastatic early recurrence (Phase II)

==> picture [314 x 70] intentionally omitted <==

• ~50 patients

• Co-funded by GenesisCare

Early data in front line care

==> picture [100 x 56] intentionally omitted <==

SELECT – radiogenomics study enhances patient selection and supports indication expansion based on a “theranostic” approach

– TARGET in partnership with GenesisCare, evaluates TLX591 in a front-line setting

Efficacy data in patients in their first recurrence

Pivotal Phase III study in patients with mCRPC progressing on 1st line novel androgen agents

• 390 patients

==> picture [428 x 69] intentionally omitted <==

TLX591 + Standard of Care (SoC) vs. SoC alone

GLOBAL (Ph III) – Multiple data read-outs throughout the ProstACT program duration

• Second line mCRPC

Telix Pharmaceuticals Limited (ASX: TLX)

ProstACT GLOBAL Ph III trial of TLX591 for the treatment of mCRPC[2] overview Study

==> picture [100 x 56] intentionally omitted <==

==> picture [126 x 31] intentionally omitted <==

TLX591 + Standard of Eligible Patients care therapy • v PSMA avid (defined by TLX591-CDx) • mCRPC Standard of care therapy • Progressed despite prior therapy with NAAD alone

==> picture [136 x 108] intentionally omitted <==

• International, multi-centre, Phase III RCT in ~390 patients with PSMA-expressing metastatic prostate cancer (mCRPC), experiencing disease progression following prior treatment with an anti-androgen drug (NAAD[1] )

• Primary endpoint: radiographic progression-free survival

• Secondary endpoints include: overall survival, quality of life, safety

• 2:1 randomisation and enrichment of study population, patient selection with TLX591-CDx

• ProstACT has been initiated in Australia and will add EU, US and potentially Chinese sites over the next six months, subject to satisfying the requisite regulator approvals

• Novel androgen axis drug

Telix Pharmaceuticals Limited (ASX: TLX)

TLX591 differentiation Antibody vs small molecule

==> picture [100 x 56] intentionally omitted <==

==> picture [43 x 43] intentionally omitted <==

==> picture [42 x 42] intentionally omitted <==

==> picture [43 x 43] intentionally omitted <==

==> picture [46 x 46] intentionally omitted <==

Significantly improved overall survival in a comparable end-stage patient Efficacy population 40+ months vs. 15.3 months[1,2 ] Reduced potential for undesirable side-effects; dry eye, xerostomia (salivary gland Patient comfort ablation), back pain (ganglia irradiation) Patient-centric Short treatment duration/significantly fewer hospital visits – two weeks total regimen vs. 36 weeks, supports close supervision by medical oncology Reduced[177] Lu isotope requirement via more targeted dosing/less waste Cost effective COGS ~1/5 of competition, expected to also be available in “cold kit” format[3]

1. Tagawa et al, Cancer 2019.

2. Cross-trial comparison, randomised controlled trial (RCT) required for verification.

3. Modelled from publicly available information.

Telix Pharmaceuticals Limited (ASX: TLX)

TLX591 patient experience Off-target irradiation – quality of life matters

==> picture [167 x 337] intentionally omitted <==

==> picture [179 x 338] intentionally omitted <==

TLX591

Antibodies are functionally specific for tumour-expressed PSMA and do not “hit” most endogenous PSMA expression Liver (preferred clearance organ) Fecal excretion

Lacrimal, Parotid, Submandibular (salivary) glands

Spleen, Liver

Kidneys, Small bowel

Bladder

(urinary excretion)

==> picture [100 x 56] intentionally omitted <==

Small molecule

Small molecule radioligands taken up by endogenous PSMA

Additional off-target effects with small molecule radioligands (not experienced with TLX591):

• Dry eye

• Xerostomia

• Back pain from ganglia irradiation

Data courtesy of Prof. Neil Bander, WCMC.

Telix Pharmaceuticals Limited (ASX: TLX)

Our long-term vision for prostate cancer Improving access, imaging and treatment options for patients

==> picture [100 x 56] intentionally omitted <==

• Further development of the PSMA target underpins our lifecycle management strategy for prostate cancer and vision to improve patient outcomes

• PSMA pipeline includes imaging, therapy and surgical tools

• NOBLE Registry (PSMA-SPECT tracer): TLX599-CDx ([99m] Tc-iPSMA) – PSMA imaging access for patients in developing and remote areas, where PET is not readily available

• Next-generation alpha therapy: TLX592 (225AcRADmAb®) – high potency, complementary to TLX591

• Image guided surgery: TLX591-Sx ([68] Ga-PSMA-IRDye) - dual-labelled PET-optical tracer for image guided surgery, enables real-time cancer detection[1]

• Imaging and Robotics in Surgery Alliance with Mauna Kea Technologies.

Telix Pharmaceuticals Limited (ASX: TLX)

Our clinical mission: Support the patient every step of the way

==> picture [100 x 56] intentionally omitted <==

Localised disease

Radiation therapy +/- ADT Radical prostatectomy PSA Active surveillance

level

Advancing clinical stages Docetaxel, abiraterone (metastatic, non-castrate), apalutamide, enzalutamide, darolutamide (non-metastatic, castrate resistant)

Metastatic castrate resistant

First line:

Docetaxel; Sipuleucel-T; Abiraterone Enzalutamide

==> picture [100 x 33] intentionally omitted <==

PSMA-617 failures

68Ga / 99mTc imaging

==> picture [117 x 39] intentionally omitted <==

==> picture [89 x 47] intentionally omitted <==

----- Start of picture text -----

Asymptomatic
Non-metastatic
Castration-sensitive
----- End of picture text -----

==> picture [663 x 214] intentionally omitted <==

----- Start of picture text -----

Rising PSA
Radiogenomics and
ADT (non-castrate)
tumour targeting of
TLX591
Combination of EBRT
and TLX591 in early
biochemical recurrence Second line +
Clinical trial
Second line:
Cabazitaxel; Abiraterone
TLX592 ( [225] Ac)
Enzalutamide; Radium 223
Olaparib; Rucaparib
Pivotal Phase III study in patients with
mCRPC progressing on 1st line novel
androgen agents
----- End of picture text -----

==> picture [87 x 47] intentionally omitted <==

----- Start of picture text -----

Symptomatic
Metastatic
Castration-resistant
----- End of picture text -----

Time / disease progression

Telix Pharmaceuticals Limited (ASX: TLX)

==> picture [100 x 56] intentionally omitted <==

Telix Pharmaceuticals Limited (ASX: TLX)

IPAX-I Phase I/II trial of TLX101 for the treatment of GBM[1]

==> picture [100 x 56] intentionally omitted <==

TLX101 in combination with EBRT[2]

• Multi-centre Phase I/II trial of TLX101 in combination with EBRT in patients with recurrent GBM

• ✓ Primary endpoint: Safety and tolerability

• NCT03849118 ✓ Secondary endpoints include: MTD[3] , efficacy, dosimetry

• NCT03849118

• First-peer review data presented at Congress of Neurological Surgeons (CNS) Annual Meeting in October 2021

• ✓ All patients evaluated received similar total activity dose of ~2GBq (2000 MBq) of TLX101, either in a single administration or a triple-fractionated regime.

• ✓ Treatment well tolerated, typically grade 1 – 2 adverse events

• ✓ Evidence of anti-tumour effect from both imaging and clinical assessment

• ✓ Overall survival (OS) on this interim analysis shows median 15.97 months to date, with three patients exhibiting stable disease at day 135 and two with stable disease at day 180

• ✓ 6/ 10 patients still alive and will be followed until 1 year after dosing for the final OS calculation (May 2022).

• Glioblastoma Multiforme.

==> picture [160 x 162] intentionally omitted <==

Baseline PET scan

==> picture [161 x 162] intentionally omitted <==

Day 45 PET scan post TLX101 therapy

1. External beam radiation therapy.

2. Maximum tolerated dose.

.[Telix Pharmaceuticals Limited (ASX: TLX)]

Follow on study IPAX-2 in planning Evaluating the potential of TLX101 in newly-diagnosed patients

==> picture [100 x 56] intentionally omitted <==

• Initial dose finding study TLX101 plus standard of care (SOC) in patients with newly diagnosed glioblastoma, after surgery

• Evaluates the potential for “DNA damage” from targeted radiation using TLX101 to enhance SOC chemotherapy for newly diagnosed glioma NCT03849118

• NCT03849118

• Study objectives expected to include:

• ✓ Maximum tolerated dose

• ✓ Safety and tolerability in combination with the Stupp regimen (SOC)

• ✓ 12 months overall survival

• ✓ Progression free survival at a range of treatment intervals

• Single-arm, multi-centre trial, expected to enrol 12-15 patients

• Patients to be treated and monitored for up to 64 weeks

• Study protocol in final stages of design, IND / ethics approval submissions expected in late 2021 / early 2022

Telix Pharmaceuticals Limited (ASX: TLX)

New hope in a rare disease Progressing development of TLX66 in bone marrow conditioning

• SALA[1] is a rare disease with a poor prognosis (median survival ~11 months if untreated)

• Plasma cells in the bone marrow produce abnormal protein called ‘amyloid’ which accumulates in the organs and causes them to fail

• NCT03849118 Prevalence of ~30,000 to 45,000 (US + EU combined) patients, ~US$600M TAM[3] in US and ‘EU5’

• Current standard of care comprises induction therapy (cyclophosphamide, bortezomib, dexamethasone) plus high dose melphalan BMC[4] , followed by HSCT[5, 6]

• A novel monoclonal antibody, daratumumab has potential as an initial therapy for patients but is not curative or suitable for all patient populations.

• TRALA study: Phase I trial of[90] Y-besilesomab (TLX66) in SALA

• ✓ Primary endpoint: Safety and toxicity of[90] Y-besilesomab as the sole BMC regimen for autologous HSCT in patients with SALA

• ✓ Study complete, preliminary data (9 pts) demonstrated 100% engraftment and high PR/CR rate (5/2) survival data. Regulator consultation in progress for next phase of development

• Systemic amyloid light chain amyloidosis.

• Bone marrow conditioning.

• https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002231-18/GB

• Hematopoietic stem cell transplant.

• Venner C, et al. Blood. (2012) 119 (19): 4387–4390.

• Total addressable market.

==> picture [100 x 56] intentionally omitted <==

==> picture [72 x 105] intentionally omitted <==

Faulty plasma cells

==> picture [32 x 243] intentionally omitted <==

Free antibody light chain

==> picture [72 x 56] intentionally omitted <==

----- Start of picture text -----

Amyloid
protein
accumulates
in organs
----- End of picture text -----

Organ failure, death

Telix Pharmaceuticals Limited (ASX: TLX)

==> picture [100 x 56] intentionally omitted <==

Future value creation Focus on innovation and growth markets

33

Telix Pharmaceuticals Limited (ASX: TLX)

Near-term growth opportunities Expansion into new geographic markets

==> picture [86 x 86] intentionally omitted <==

==> picture [527 x 285] intentionally omitted <==

• DuChemBio partnership

• Launch Illuccix with distribution partner (in progress)

• NECA HTA[1] completed

• NOBLE Registry expansion

• Illuccix kit sales have commenced, pursuing reimbursement

• National Evidence-based Healthcare Collaborating Agency. Health Technology Assessment.

==> picture [100 x 56] intentionally omitted <==

• China Grand Pharma partnership

• • NMPA consultations have commenced (Mainland China)

• Regulatory filings for Illuccix Q1 2022 (Taiwan, Hong Kong)

• Largest Asia Pacific market opportunity

Key bridging clinical trials have been successfully completed (TLX591-CDx & TLX250-CDx)

Telix Pharmaceuticals Limited (ASX: TLX)

Buildout of the Brussels (Seneffe) manufacturing facility Vertical integration in Europe

==> picture [100 x 56] intentionally omitted <==

• Seneffe will serve as the primary EU manufacturing site for Telix’s products

==> picture [468 x 350] intentionally omitted <==

• ✓ Will also be used manufacture 131I-based products for

• NCT03849118 export (i.e. TLX101) using Belgian-sourced isotopes

• NCT03849118 (Belgium is a major global supplier)

• ✓ One of the deepest isotope production licences in Europe

• ✓ Provides certainty / control over supply chain

• Seneffe will be an integral part of Telix’s EU R&D capability

• Allows us to capture the IP that is intrinsic in manufacturing scale-up of this class of drugs

✓ Buildout has commenced

• ✓ First cyclotron removed October 2021, second scheduled for November 2021

• ✓ Removed in one piece, with the aim to recycle as much material as possible

• Build of two new cyclotrons to commence in early 2022

Telix Pharmaceuticals Limited (ASX: TLX)

Future research and innovation focus

==> picture [104 x 58] intentionally omitted <==

==> picture [145 x 144] intentionally omitted <==

==> picture [179 x 179] intentionally omitted <==

==> picture [178 x 179] intentionally omitted <==

==> picture [144 x 144] intentionally omitted <==

==> picture [145 x 144] intentionally omitted <==

Targeted alpha MTR + Tumour Artificial Radio-guided therapy immuno-oncology microenvironment intelligence (AI) surgery "Next Generation" MTR sets the Combining MTR with Tools to Bringing molecular therapeutics with “groundwork” for standard of care maximise clinical insigh imaging into the alpha-emitting cancer immunotreatments for ts gained from imaging, operating room (OR) improved efficacy with radioisotopes therapy in combination link to therapeutic biomarker-driven outcomes patient selection

36

Telix Pharmaceuticals Limited (ASX: TLX)

Near-Term Catalysts

==> picture [104 x 58] intentionally omitted <==

Calendar Q4 2021

• Illuccix EU “clock stop” for final review (end-Nov)

• Illuccix US FDA decision (PDUFA goal date 23 Dec 2021)

• Distributors finalised for EU product launch

• First ProstACT patients

• • Calendar Q1 2022

• STARLITE 1/2 trials active (FDA IND approval) and recruiting

• Illuccix EU marketing authorisation decision

• HCPCS reimbursement submission for Illuccix in the US (Jan)

• ZIRCON trial enrolment completed

• IPAX-2 study launched (glioblastoma)

• US, AU Illuccix product launch

37

Telix Pharmaceuticals Limited (ASX: TLX)

==> picture [271 x 234] intentionally omitted <==

==> picture [176 x 97] intentionally omitted <==

Precision Oncology See it. Treat it.

www.telixpharma.com IR contact: Kyahn Williamson Email: kyahn.williamson@telixpharma.com